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PURPOSE. Current treatments for diabetic retinopathy (DR) have considerable limitations,
underpinning the need for new therapeutic options. In this article, the ability of an
engineered angiopoietin-1 variant (COMP-Ang1) to ameliorate the injurious effects of
hyperglycemia on barrier integrity in a human retinal microvascular endothelial cell
(HRMvEC) model is comprehensively investigated.
METHODS. Confluent HRMvECs were treated (0–72 hours) with D-glucose (5 or 30 mM) in the
absence and presence of COMP-Ang1 (10–200 ng/mL). L-glucose (30 mM) was used as
osmotic control. Posttreatment, intact cell monolayers were monitored for permeability to
FITC-dextran 40 kDa. Cells were also harvested for analysis of interendothelial junction targets
by RT-qPCR and Western blotting. The impact of receptor tyrosine kinase Tie2 gene silencing
on COMP-Ang1 efficacy was also evaluated.
RESULTS. Treatment with 30 mM D-glucose (but not L-glucose) demonstrated a time-dependent
elevation in the mean rate of FITC-dextran diffusion across intact HRMvEC monolayers, in
parallel with significant reductions in mRNA/protein levels of occludin, claudin-5, ZO-1, and
VE-Cadherin. These effects were all attenuated by COMP-Ang1 in a concentration-dependent
fashion, with 200 ng/mL recovering barrier function by ~88%, and recovering reduced
interendothelial junction protein levels by more than 50%. Finally, Tie2 knockdown by small
interfering RNA silencing blocked the ability of COMP-Ang1 to mitigate against hyperglyce-
mia-induced permeabilization of HRMvECs and depletion of junctional expression levels.
CONCLUSIONS. In summary, this article presents a reproducible in vitro cell study that quantifies
the concentration-dependent efficacy of COMP-Ang1 to mitigate the injurious effects of
hyperglycemic challenge on HRMvEC barrier properties via Tie2-mediated signaling.
Keywords: endothelial, diabetic retinopathy, COMP-Ang1, Tie2, blood-retinal barrier
Type-1/2 diabetes mellitus (DM), with its high mortality ratedirectly linked to vascular and renal complications, is fast
becoming one of the leading global causes of death, placing
enormous strain on health care systems.1 Diabetic retinopathy
(DR) is one of the main global causes of blindness in working-
age individuals, affecting both type-1/2 diabetic individuals. DR
is a degenerative disease of retinal capillaries and associated
neuroglial cells, collectively manifesting impaired retinal vaso-
regulation, elevated microvascular permeability, microaneu-
rysm formation, cell death, and ultimately, widespread
nonperfusion and ischemia of the inner retina.2–4
Several novel therapeutic approaches to DR have focused on
limiting damage to the microvascular endothelial cells that form
the retinal capillary lumen at the frontline of hyperglycemic
attack. Both in vitro and in vivo strategies targeting connexin 43
(Cx43) gap junctions,5,6 VEGF receptors-1/2,7 and the Tie2
receptor pathway8 have previously been used, with varying
degrees of success. Using human primary retinal endothelial
cells, Stewart et al.9 also recently reported beneficial effects of
dexamethasone to reverse the permeabilizing effects of
hyperglycemia by restoring the cellular balance between the
Tie2-activating ligand, angiopoietin-1 (Ang1), and its context-
dependent antagonist, angiopoietin-2 (Ang2).
With respect to Ang1, substitution of the N-terminal portion
of this ligand with the short coiled-coil domain of cartilage
oligomeric matrix protein has yielded a soluble and stable Ang1
variant (COMP-Ang1) with therapeutic potential for treating
endothelial inflammation and vascular leakage.10 In this study,
we hypothesized that COMP-Ang1 could ameliorate the
injurious effects of hyperglycemia on barrier integrity in a
human retinal microvascular endothelial cell (HRMvEC) model
of DR. In support of this hypothesis, a limited number of mainly
in vivo studies have previously reported the ability of COMP-
Ang1 to improve microvascular function. Cho et al.11 showed
that COMP-Ang1 can promote wound healing through en-
hancement of angiogenesis and blood flow in diabetic db/db
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mice, whereas Chen et al.12 demonstrated that COMP-Ang1
can protect endothelial barriers in rats with acute necrotizing
pancreatitis. Subretinal and intravitreal delivery of COMP-Ang1
cloned into an adeno-associated virus vector (AAV2.COMP-
Ang1) exhibited microvasculature-related improvements in
mouse models of AMD13 and diabetic retinopathy,14 respec-
tively. To our knowledge however, there are no in vitro retinal
microvascular endothelial cell studies delineating the precise
mechanistic impact of COMP-Ang1 on hyperglycemia-induced
injury to the interendothelial junction complex.
To address this issue, we pursued three key aims: (1) to
establish a reproducible model of hyperglycemia-induced
HRMvEC barrier disruption; (2) to quantitatively assess the
impact of COMP-Ang1 treatment on HRMvEC barrier proper-
ties under hyperglycemic challenge; and (3) to evaluate the




Unless otherwise stated, all reagents were purchased from
Sigma-Aldrich (Dublin, Ireland). Western blotting primary
antisera were purchased from the following sources: anti-
occludin IgG, anti-claudin-5 IgG, and anti-ZO-1 IgG (Thermo
Fischer Scientific, Dublin, Ireland); anti-VE-Cadherin IgG
(Abcam, Cambridge, UK); anti-b-actin (Cell Signaling Technol-
ogies Inc., Danvers, MA, USA). Horseradish peroxidase (HRP)-
conjugated secondary antisera for all targets were purchased
from Cell Signaling Technologies Inc. COMP-Ang1 was
purchased from Enzo Life Sciences (Exeter, UK). For Tie2
experiments, dual Ambion Silencer Select small interfering
RNA (siRNA) constructs (assay IDs 13983 and s13984 against
TEK/Tie2) were purchased from Thermo Fisher Scientific. An
anti-Tie2 IgG and associated donkey anti-goat secondary IgG
were purchased from R&D Systems (Abingdon, UK).
Cell Culture
Primary HRMvECs were acquired from Cell Systems (Kirkland,
WA, USA) and routinely cultured in EndoGRO MV Endothelial
Medium (MerckMillipore, Cork, Ireland) containing 100 units
of penicillin and 100 lg of streptomycin per milliliter of
medium. All cells (passages 5–12) were grown on attachment
factor–coated tissue culture grade plastic-ware and maintained
in a humidified atmosphere of 5% CO2/95% air at 378C.
Confluent cells were treated with either D-glucose (5 or 30
mM) or L-glucose (osmotic control, 30 mM) for up to 72 hours.
For specific experiments, COMP-Ang1 (10, 100, or 200 ng/mL)
was incorporated into the treatment regimen. Following
treatments, intact cell monolayers were either monitored for
changes in barrier function via trans-endothelial permeability
assay or cells were harvested for analysis of mRNA and protein
expression. Details on the preparation of mRNA and whole cell
protein lysates have been described in detail previously.15 All
samples were stored at 808C until required. Effects of all
treatments on cell viability (including siRNA transfection
described below) were routinely monitored using either MTT
formazan dye or crystal violet assay.
Trans-endothelial Permeability Assay
HRMvECs were seeded into transwell inserts at a density of
500,000 cells/well and allowed to grow to confluency. The
analysis of HRMvEC monolayer permeability following various
treatments used transwell diffusion of FITC-labeled 40 kDa
dextran as previously described in detail by Walsh et al.16
Permeability results were expressed as the mean rate of FITC-
dextran trans-endothelial exchange (%FD40TEE.min
1).
Reverse-Transcriptase Quantitative PCR (RT-qPCR)
Following experiments, HRMvECs were harvested for extrac-
tion of total RNA, preparation of cDNA, and amplification of
target cDNA sequences by RT-qPCR (Thermocycler; Roche
Diagnostics, West Sussex, UK) as previously described in
Guinan et al.17 with minor modifications. PCR reaction
mixtures (12 lL) were as follows: 6 lL of FastStart Universal
SYBR Green/Rox Mastermix (Roche Diagnostics, West Sussex,
UK), 2 lL RNAse-free water, 2 lL cDNA, and 1 lL each 10 lM
forward and reverse primers. PCR reaction conditions were as
follows: denaturation at 958C for 10 minutes followed by 40
cycles of (1) denaturation at 958C for 15 seconds, (2) annealing
at 598C for 60 seconds, and (3) elongation at 728C for 15
seconds. Each cDNA sample was assayed in triplicate and
results analyzed by the comparative CQ method. For normal-
ization purposes, b-actin was routinely used. All primer pairs
were screened for correct product size (1% agarose gel
electrophoresis) and underwent melt-curve analysis for prim-
er-dimers. b-actin (218 bp): Forward 50-catccgcaaagacctgtacg-
3 0; Reverse 5 0-cctgcttgctgatccacatc-3 0; Occludin (224 bp):
Forward 50-ccttcacccccatctgacta-3 0; Reverse 50-gcaggtgctcttttt-
gaagg-30; Claudin-5 (240 bp): Forward 50-gaggcgtgctctacctgttt-
30; Reverse 50-agtacttcacggggaagctg-3 0; ZO-1 (218 bp): Forward
50-gaacgaggcatcatccctaa-3 0; Reverse 50-ccagcttctcgaagaaccac-3 0;
VE-Cadherin (185 bp): Forward 50-cagcccaaagtgtgtgagaa-30;
Reverse 50-cggtcaaactgcccaactt-3 0; Tie2 (222 bp): Forward 50-
tcatgaactggtgaccctcc-3 0; Reverse 50-agtccctgagttgaactgca-3 0.
Western Immunoblotting
Following experiments, HRMvEC cell lysates were harvested,
resolved by 8% SDS-PAGE under reducing conditions, and
electroblotted as previously described.18 Primary antisera: 0.5
lg/mL anti-occludin, anti-claudin-5, and anti-ZO-1 mouse
monoclonal IgGs; 0.2 lg/mL anti-VE-Cadherin mouse mono-
clonal IgG; 1/1000 anti-Tie2 goat monoclonal IgG; and 0.2 lg/
mL anti-b-actin rabbit monoclonal IgG. Secondary antisera:
1:2000 HRP-conjugated goat anti-mouse IgG (occludin, claudin-
5, ZO-1, and VE-Cadherin), 1:2000 HRP-conjugated donkey
anti-goat IgG (Tie2), and 1:3000 HRP-conjugated goat anti-
rabbit IgG (b-actin). Membranes were developed using a
Luminata Western HRP kit (MerckMillipore), followed by
chemiluminescent imaging using a G-Box gel-documentation
system (Syngene, Cambridge, UK). Scanning densitometry of
Western blots was performed using NIH ImageJ software
(http://imagej.nih.gov/ij/; provided in the public domain by
the National Institutes of Health, Bethesda, MD, USA), with b-
actin routinely used as a loading control to facilitate
densitometric normalization of bands.
Tie2 siRNA Studies
To assess the extent to which COMP-Ang1 potentially exerts its
effects through the Tie2 receptor, molecular inhibition of Tie2
using siRNA knockdown was performed. Scrambled (Ambion
Silencer Select Negative Control No.1 and No.2) and Tie2
(Ambion Silencer Select Tie2 siRNA, ID: s13983 and s13984)
siRNAs were used. For siRNA transfection into HRMvECs, a
Microporator system was used (Life Technologies, Paisley, UK)
as previously described.17 Optimization studies were initially
performed on HRMvECs to confirm Tie2 knockdown efficiency
and to determine optimal siRNA working conditions. For these
optimization studies, we tested siRNA constructs either
individually (0–50 nM) or in combination/duplex (0–50 nM
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per construct) for up to 72 hours. Levels of Tie2 knockdown
were assessed by RT-qPCR and Western Blotting. Mock
transfections (excluding siRNA) were routinely included for
control purposes.
Statistical Analysis
Results are expressed as mean 6 SD. Experimental points were
performed in triplicate with a minimum of three independent
experiments (n ¼ 3). Statistical comparisons between control
and experimental groups were by ANOVA in conjunction with
a Dunnett’s post hoc test for multiple comparisons. A Student’s
t-test was also routinely used for pairwise comparisons. A value
of P  0.05 was considered significant.
RESULTS
Hyperglycemia Reduces HRMvEC Barrier Function
To better understand the precise impact of hyperglycemia on
retinal barrier function in vitro, we investigated the effects of D-
glucose on HRMvEC permeability. Confluent HRMvECs were
treated for up to 72 hours with either 5 mM D-glucose
(normoglycemia), 30 mM D-glucose (hyperglycemia), or 30 mM
L-glucose (osmotic control). Trans-endothelial permeability
assays clearly demonstrated a time-dependent elevation in the
mean rate of FITC-dextran diffusion across intact HRMvEC
monolayers in response to hyperglycemia, showing a 70%
increase after 72 hours with 30 mM D-glucose. Diffusion rates
over the same period remained unchanged under normogly-
cemic conditions and in the 30-mM L-glucose control (Fig. 1).
In parallel studies, we also examined how these conditions
affected the expression of interendothelial junctions at both
the mRNA and protein levels. In response to 30 mM D-glucose,
HRMvECs showed a time-dependent decrease (68%–74%) in
mRNA levels for occludin, claudin-5, zonula occludens-1 (ZO-
1), and VE-Cadherin (Fig. 2A). This was also reflected at the
protein level with decreases ranging from 74% to 89% (Figs. 2B,
2C). Importantly, 30 mM L-glucose did not elicit any changes in
the mRNA or protein levels for any of these proteins over the
72-hour treatment period (Supplementary Figs. S1A–C).
COMP-Ang1 Significantly Attenuates the
Hyperglycemia-Induced Reduction in HRMvEC
Barrier Function
We next investigated the ability of COMP-Ang1 to attenuate the
effects of hyperglycemia on HRMvEC barrier properties.
Confluent HRMvECs were treated for up to 72 hours with
either 5 mM D-glucose (normoglycemia) or 30 mM D-glucose
(hyperglycemia) in the absence and presence of recombinant
COMP-Ang1 (10–200 ng/mL). Under hyperglycemic condi-
tions, a significant elevation in the mean rate of FITC-dextran
diffusion across intact HRMvEC monolayers was observed. We
also observed that hyperglycemia-induced permeabilization
could be significantly reduced in a concentration-dependent
manner by COMP-Ang1, with 200 ng/mL recovering barrier
function by approximately 88% (Fig. 3). In parallel studies, we
examined the effects of COMP-Ang1 on the hyperglycemia-
induced reduction of interendothelial junctions. Our data
clearly demonstrated that COMP-Ang1 could significantly
reverse, in a concentration-dependent manner, the injurious
effects of hyperglycemia on occludin, claudin-5, ZO-1, and VE-
Cadherin with recovery of depleted mRNA levels ranging from
13% (at 10 ng/mL COMP-Ang1) to 53% (at 200 ng/mL COMP-
Ang1) (Figs. 4A–D). Similar concentration-dependent recovery
effects with COMP-Ang1 treatment also were observed for all
interendothelial junction protein levels (Figs. 5A–D). Finally,
treatment of HRMvECs with up to 200 ng/mL COMP-Ang1
under either normoglycemic or hyperglycemic conditions had
no observable effects on cell viability (data not shown).
COMP-Ang1 Stabilizing Effects in HRMvECs Under
Hyperglycemia Operate Through the Tie2
Receptor Pathway
In a final round of experiments, we investigated the
mechanistic contribution of the Tie2 receptor pathway toward
mediating the beneficial effects of COMP-Ang1 on HRMvECs
during hyperglycemic challenge. In pre-optimization studies
with HRMvECs, a duplex combination of two Ambion Silencer
Select Tie2 siRNAs elicited up to 85% knockdown of Tie2
mRNA levels and 75% knockdown of Tie2 protein levels (50
nM per siRNA, 12 hours post-transfection). Scrambled siRNA
FIGURE 1. D-glucose causes permeabilization of HRMvECs. Cells were treated for up to 72 hours with either 5 mM D-glucose (normoglycemic), 30
mM D-glucose (hyperglycemic), or 30 mM L-glucose (osmotic control). HRMvEC monolayer barrier integrity was then monitored by transendothelial
permeability assay (i.e., mean rate of FITC-dextran diffusion: %FD40 TEE.min
1). *P  0.05 versus 0-hour control.
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had no effect (Supplementary Figure S2). Moreover, siRNA
treatment of HRMvECs had no observable effects on cell
viability under these conditions (data not shown). In subse-
quent experiments, Tie2 knockdown was found to completely
block the ability of COMP-Ang1 to mitigate against hypergly-
cemia-induced permeabilization of HRMvECs (Fig. 6). Likewise,
the ability of COMP-Ang1 to reverse the considerable
hyperglycemia-induced depletion in mRNA (Fig. 7) and protein
(Fig. 8) expression levels of interendothelial junction targets
was completely blocked as a consequence of Tie2 silencing.
FIGURE 2. D-glucose reduces interendothelial junction expression in HRMvECs. Cells were treated for up to 72 hours with 30 mM D-glucose
(hyperglycemic). HRMvECs were then harvested and monitored by (A) quantitative PCR and (B) Western blotting for levels of occludin, claudin-5,
ZO-1, and VE-Cadherin. Histograms in (B) represent densitometric fold changes in Western blot band intensity relative to 0-hour controls. A
representative set of blots (0–72 hours) is shown in (C). *P  0.05 versus 0-hour control.
FIGURE 3. COMP-Ang1 attenuates hyperglycemia-induced permeabilization of HRMvECs. Cells were treated for 48 hours with either 5 mM D-
glucose (normoglycemic) or 30 mM D-glucose (hyperglycemic) in the absence and presence of COMP-Ang1 (10, 100, or 200 ng/mL). HRMvEC
monolayer barrier integrity was then monitored by transendothelial permeability assay (i.e., mean rate of FITC-dextran diffusion: %FD40 TEE.min
1).
*P  0.05 versus untreated normoglycemic control. dP  0.05 versus 30 mM D-glucose.
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DISCUSSION
Current therapeutic options for DR, a blinding disease that
seriously affects quality of life in type-1/2 diabetic patients,
have significant limitations. Rates of improvement in visual
function following 5-year ranibizumab treatment were 33% and
23%, respectively, for nonproliferative and proliferative DR.19
Likewise, other anti-VEGF agents like VEGF-Trap Eye achieved
similar gains in only approximately 34% of DR patients.20
Moreover, frequent intravitreal injections of anti-VEGF agents
carry risks of pain, vitreous hemorrhage, retinal detachment,
and endophthalmitis.21 Laser photocoagulation therapy, a
traditional mainstay of DR therapy, carries the disadvantage
of creating burns that can reduce peripheral vision, central
vision, and/or night vision.22 Improved therapeutic options for
DR are therefore clearly warranted.
In recent years, attention has focused on using COMP-Ang1,
a soluble, stable angiopoietin-1 variant,10 in models of DR.
Recent studies using diabetic murine models have reported the
ability of COMP-Ang1 to improve microvascular function by
promoting wound healing and enhanced visual acuity.11,13,14
By delineating the precise mechanistic impact of COMP-Ang1
on the retinal interendothelial junction in vitro, our study lends
important insight into physiologically elevated microvascular
leakage and vessel destabilization during DR pathology.
To this end, we first established a comprehensive and
reproducible model of hyperglycemia-induced HRMvEC barrier
disruption with the intention of broadening the experimental
depth of existing HRMvEC model equivalents (e.g., testing
multiple drug concentrations and glucose exposure times to
establish dose/time-dependency criteria, quantitatively investi-
gating a broad range of adherens and tight junction proteins at
both the mRNA and protein levels, and using L-glucose as an
osmotic control in all studies given the now-established
confounding signaling effects of mannitol23). This undertaking
is also necessitated by the fact that certain widely used retinal
cell models such as bovine retinal endothelial cells (BRECs)
exhibit poor/variable glucose responsiveness.24 Following
chronic hyperglycemic challenge with 30 mM D-glucose, intact
HRMvEC monolayers exhibited a robust time-dependent
increase in the transendothelial diffusion rate of FITC-dextran,
in parallel with decreased expression (both mRNA and protein)
of the interendothelial junction proteins essential to mainte-
nance of barrier integrity (i.e., occludin, claudin-5, ZO-1, and
VE-Cadherin). These results mirror the hyperpermeabilizing
effects of high glucose recently reported for rat retinal
endothelial cells,6 as well as in human primary retinal
endothelial cells,9 which additionally showed reduced mRNA
levels of claudin-5, occludin, and JAM-A. With respect to this
latter study of Stewart et al.,9 it can be noted, however, that
glucose had no effect on VE-Cadherin levels in HRMvECs, a
clear contrast to the current study. This may point to
heterogeneity in different commercial preparations of
HRMvECs and/or variations in experimental approach.
In subsequent experiments, we demonstrated that all of the
aforementioned harmful glucose-dependent effects on barrier
integrity and interendothelial junctions can be substantively
ameliorated by cotreatment of HRMvECs with COMP-Ang1. An
additional statistical comparison (not shown) between the
COMP-Ang1/normoglycemia versus COMP-Ang1/hyperglyce-
mia conditions for our experiments also regularly demonstrates
statistically significant differences, leading us to deduce that
FIGURE 4. COMP-Ang1 attenuates hyperglycemia-induced reduction in interendothlelial junction mRNA expression in HRMvECs. Cells were treated
for 48 hours with either 5 mM D-glucose (normoglycemic) or 30 mM D-glucose (hyperglycemic) in the absence and presence of COMP-Ang1 (10,
100, or 200 ng/mL). HRMvECs were then harvested and monitored by qPCR for mRNA expression of (A) Occludin, (B) Claudin-5, (C) ZO-1, and (D)
VE-Cadherin. *P  0.05 versus untreated normoglycemic control; dP  0.05 versus 30 mM D-glucose.
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COMP-Ang1 is not fully restoring the damaging effects of
hyperglycemia, even at the 200 ng/mL concentration.
Consistent with our in vitro findings, COMP-Ang1 was
previously found to prevent endotoxin-induced vascular
leakage in mice, in part by restoring expression of platelet
endothelial cell adhesion molecule-1 (PECAM-1) within inter-
endothelial junctions.25 Our findings also bring some valuable
mechanistic insight into the recent in vivo study of Cahoon et
FIGURE 5. COMP-Ang1 attenuates hyperglycemia-induced reduction in interendothlelial junction protein expression in HRMvECs. Cells were
treated for 48 hours with either 5 mM D-glucose (normoglycemic) or 30 mM D-glucose (hyperglycemic) in the absence and presence of COMP-Ang1
(10, 100, or 200 ng/mL). HRMvECs were then harvested and monitored by Western blotting for protein expression of (A) Occludin, (B) Claudin-5,
(C) ZO-1, and (D) VE-Cadherin. Histograms represent densitometric fold changes in Western blot band intensity relative to untreated
normoglycemic control. A representative set of blots for 10, 100, and 200 ng/mL COMP-Ang1 is shown in (E). *P  0.05 versus untreated
normoglycemic control; dP  0.05 versus 30 mM D-glucose.
FIGURE 6. COMP-Ang1 attenuates hyperglycemia-induced permeabilization of HRMvECs: impact of Tie2 siRNA. Based on gene silencing treatment,
cells were divided into four groups: Control, Mock Transfected (i.e., no siRNA), Scrambled siRNA, and Tie2 siRNA. Cells were then treated for 48
hours with either 5 mM D-glucose (normoglycemic) or 30 mM D-glucose (hyperglycemic) in the absence and presence of 200 ng/mL COMP-Ang1.
HRMvEC monolayer barrier integrity was then monitored by transendothelial permeability assay (i.e., mean rate of FITC-dextran diffusion: %FD40
TEE.min1). *P  0.05 versus untreated normoglycemic control. dP  0.05 versus 30 mM D-glucose.
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al.,14 who demonstrated how Evans Blue extravasation and
GFP-microsphere leakage from the retinal capillary microvas-
culature in diabetic Ins2Akita mice can be robustly prevented
by COMP-Ang1 treatment, likely via restoration of the
depeleted interendothelial barrier. It should be noted that this
latter study also reported the ability of COMP-Ang1 to increase
transendothelial electrical resistance (TER) and VE-Cadherin
expression in HRMvECs under normoglycemia, but unlike the
present article, does not examine drug effects under hypergly-
cemia.
Within the adult vasculature, Ang1 agonist-induced Tie2
activation is known to promote endothelial barrier stabilization
and vascular quiescence, and as such, has become an
important focus of therapeutic strategies targeting pathologies
of vascular activation, such as DR.26,27 We therefore decided to
confirm that the beneficial COMP-Ang1 effects on HRMvECs
under hyperglycemia were putatively mediated through the
canonical Ang1:Tie2 receptor system, the latter Tie2 receptor
tyrosine kinase being highly enriched within the endothelium.
In support of this, an early study by Cho et al.10 clearly
demonstrates the ability of COMP-Ang1 to temporally activate
Tie2 in human umbilical vein endothelial cells (HUVECs). The
functional relevance of this observation is further demonstrat-
ed by Oh et al.,8 who showed that COMP-Ang1 can suppress
vascular leakage in mice and improve cell survival and
angiogenesis in HUVECs through the Tie2 receptor system.
Other HUVEC studies by Sturk et al.,28 Moon et al.,29 and Qiu
et al.30 also provide evidence of COMP-Ang1–mediated Tie2
activation with downstream consequences for tyrosine phos-
phorylation of growth factor receptor-bound (Grb) adaptor
proteins, neovascularization and wound-healing processes, and
paracrine signaling to nonvascular cell types (e.g., dorsal root
ganglion neurons).
To confirm a role for Tie2 in our HRMvEC experiments, we
optimized a commercially sourced siRNA duplex to achieve
robust silencing of Tie2 expression in HRMvECs. The inability
of COMP-Ang1 to ameliorate hyperglycemia-induced effects in
HRMvECs after siRNA-mediated Tie2 silencing strongly sup-
ports our hypothesis that the beneficial effects of COMP-Ang1
on barrier integrity during hyperglycemia are mediated
through a COMP-Ang1:Tie2 interaction. Interestingly, COMP-
Ang1 also reduces HRMvEC permeability under normoglyce-
mic conditions, an effect that does not appear to be influenced
by Tie2 silencing (see Fig. 6). This may reflect a duality in
COMP-Ang1 mode-of-action toward paracellular permeability
possibly stemming from COMP-Ang1 operating through
distinct signaling pathways under normoglycemic versus
hyperglycemic states. Alternately, it may be attributable to
alterations in endothelial Tie2 receptor levels in response to
elevated glucose. Future investigations will address this
interesting issue more closely.
In summary, this article presents a reproducible in vitro cell
study confirming the concentration-dependent efficacy of
COMP-Ang1 to mitigate the injurious effects of hyperglycemic
challenge on HRMvEC barrier properties. A clear role for
COMP-Ang1:Tie2 interaction also is confirmed. These observa-
tions provide timely mechanistic support to recent murine
studies and serve as a basis for further investigations into the
therapeutic value of modulating the Tie2 signaling axis during
inflammatory microvascular diseases of the eye.
FIGURE 7. COMP-Ang1 attenuates hyperglycemia-induced reduction in interendothlelial junction mRNA expression in HRMvECs: impact of Tie2
siRNA. Based on gene silencing treatment, cells were divided into four groups: Control, Mock Transfected (i.e., no siRNA), Scrambled siRNA, and
Tie2 siRNA. Cells were treated for 48 hours with either 5 mM D-glucose (normoglycemic) or 30 mM D-glucose (hyperglycemic) in the absence and
presence of 200 ng/mL COMP-Ang1. HRMvECs were then harvested and monitored by qPCR for mRNA expression of (A) Occludin, (B) Claudin-5,
(C) ZO-1, and (D) VE-Cadherin. *P  0.05 versus untreated normoglycemic control; dP  0.05 versus 30 mM D-glucose.
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